Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer - Seite 3

Forward-Looking Statements

This press release contains statements that constitute "forward-looking statements" including, but not limited to, expectations with respect to enrollment of additional patients in, and receiving results from, Celcuity's Phase 3 VIKTORIA-1 clinical trial, expectations with respect to potential results from such trial and the ability of such results to support future regulatory submissions, expectations for the efficacy and safety of gedatolisib, expectations with respect to the closing of Celcuity's $100 million private placement, the $20 million term loan and the impact such financing sources will have on the Company's balance sheet and liquidity needs. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "intends" or "continue," and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Forward-looking statements are subject to numerous risks, uncertainties, and conditions, many of which are beyond the control of Celcuity. These include, but are not limited to, those risks set forth in the Risk Factors section in Celcuity's Quarterly Report for the period ended September 30, 2022 filed with the Securities and Exchange Commission on November 10, 2022. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Celcuity undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.

Contacts:

Celcuity Inc.
Brian Sullivan, [e-mail]
Vicky Hahne, [e-mail]
[phone]

ICR Westwicke
Robert Uhl, [e-mail]
[phone]

SOURCE: Celcuity Inc.

View source version on accesswire.com:
https://www.accesswire.com/730704/Celcuity-Announces-First-Patient-Dos ...


The Celcuity Stock at the time of publication of the news with a fall of -6,71 % to 7,51USD on Nasdaq stock exchange (07. Dezember 2022, 21:44 Uhr).